Non-depleting CD4-specific monoclonal antibodies for the treatment of insulin-dependent diabetes mellitus (IDDM)
AssigneesUniversity College London, Glaxo Wellcome Inc.
InventorsAnne Cooke, Herman Waldmann
Life of this patent
Estimating the term…
Abstract
Non-depleting CD4 monoclonal antibodies may be used in the treatment of insulin-dependent diabetes mellitus.
Claims9
A method of arresting the loss of insulin-producing cells in a host subject to such loss which comprises administering to the host an effective amount administered being sufficient CD4 monoclonal antibody the amount administered being sufficient to arrest the loss of insulin-producing cells.
A method of treatment of insulin dependent diabetes mellitus which method comprises administering to a patient in need thereof an effective, non-toxic amount of at least one non-depleting CD4 monoclonal antibody.
Dependencies are inferred from the claim text.